Kezar Life Sciences Announces Presentations of Four Abstracts at the 2019 ACR/ARP Annual Meeting
October 01, 2019 16:05 ET
|
Kezar Life Sciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...
Kezar Life Sciences to Present at the 2019 Cantor Global Healthcare Conference
September 27, 2019 14:22 ET
|
Kezar Life Sciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...
Kezar Life Sciences Announces Presentations at Upcoming Investor Conferences
August 28, 2019 16:05 ET
|
Kezar Life Sciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...
Kezar Life Sciences Reports Second Quarter 2019 Financial Results and Provides Business Update
August 07, 2019 16:05 ET
|
Kezar Life Sciences, Inc.
Promising data reported from the Phase 1b portion of MISSION, a first-in-patient study of KZR-616; Phase 2 portion of MISSION in LN patients has been initiatedPhase 2 PRESIDIO and MARINA trials have...
Kezar Life Sciences Announces Promising Data from First in Patient Study of KZR-616 at EULAR 2019 Annual Meeting
June 13, 2019 16:01 ET
|
Kezar Life Sciences, Inc.
Repeat dosing of KZR-616 demonstrates tolerability and broad and consistent evidence of efficacy across multiple measures of disease activityPatients receiving KZR-616 have not experienced the...
Kezar Life Sciences to Host Conference Call and Webcast at the EULAR 2019 Annual Meeting to Discuss Results of First in Patient Study with KZR-616
June 10, 2019 16:05 ET
|
Kezar Life Sciences, Inc.
SOUTH SAN FRANCISCO, Calif., June 10, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...
Kezar Life Sciences Announces Acceptance of Abstract for Presentation of First in Patient Study with KZR-616 at EULAR 2019 Annual Meeting
May 28, 2019 07:00 ET
|
Kezar Life Sciences, Inc.
Abstract highlights preliminary results from the first two cohorts of the Phase 1b portion of the MISSION Trial in patients with systemic lupus erythematosus (SLE)Detailed poster with additional...
Kezar Life Sciences Announces Presentations at Two Upcoming Investor Conferences
May 14, 2019 16:05 ET
|
Kezar Life Sciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 14, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...
Kezar Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update
May 07, 2019 16:05 ET
|
Kezar Life Sciences, Inc.
Phase 1b systemic lupus erythematosus (SLE) top-line data release and Phase 2 lupus nephritis (LN) initiation on track in Q2 2019Site selection underway for Phase 2 trial of KZR-616 for the treatment...
Kezar Life Sciences to Present at the 18th Annual Needham Healthcare Conference
April 03, 2019 08:00 ET
|
Kezar Life Sciences, Inc.
SOUTH SAN FRANCISCO, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule...